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scenarios when compared to PCV13 alone [-328 (-1.6%) to 2,268 (9,2%) and from 
-10,145 (-8.9%) to 3,972 (4%) for IPD and NBPP respectively]. From a budget impact 
standpoint, none of the scenario was found in favor of PCV13. Under conservative 
vaccination coverage assumptions, the total incremental budget impact if PCV13 
replace PPV23 for the immunocompetent population ranged from € 39.8 million to 
€ 69.3 million. ConClusions: With the epidemiological changes of pneumococcal 
diseases and the wider serotype coverage of PPV23, vaccination of at risks adults 
with PPV23 remains the optimal one strategy from a public health perspective. 
Moreover, in the current health budget constraint, PCV13 alone is found to be associ-
ated with a significant impact on budget, whereas the health benefits are limited.
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objeCtives: This study aimed to evaluate the impact of pneumonia, meningitis 
and sepsis and the how they represent the costs for patients 50 years and older in 
the Brazilian Private Health System. Methods: An administrative claims database 
containing over 18 million lives was used to identify episodes of pneumonia, men-
ingitis and sepsis, in all ages, between Oct/2010 and Dec/2013. The episodes were 
identified using ICD-10 codes of A40.3; B95.3; G00.1; J13; J15; J15.0; J15.3; J15.4; J15.8; 
J15.9; J18; J18.0; J18.9; J20.2 and P23.3 for pneumonia, A40; A40.0; A40.1; A40.8; A40.9; 
A41.8; A41.9; P36; P36.0 and P36.1 for sepsis, G00 and G00.9 for meningitis. Patients 
aged ≥ 50 years were identified and all-cause costs were extracted and grouped 
according to the 3 disease conditions. Results: A total of 70,850 patients were 
identified (pneumonia: 68,717; sepsis: 1,745; meningitis: 388, representing 96.99%, 
2.46% and 0.55% respectively). Different diseases disproportionately affected the 
populations. For pneumonia, 11.71% of episodes were in the ages 50+. Meningitis 
and sepsis represents 5.15% and 42.35%, respectively. The cost burden was also dif-
ferent by disease. Pneumonia had 56.95% of costs incurred by age 50+. For sepsis 
and meningitis, 75.8% and 15.53% of the costs were incurred by age 50+, respec-
tively. ConClusions: Pneumonia, meningitis, and sepsis and its associated costs 
disproportionately affect the population in the Brazilian private health system. In 
particular, proportion of all pneumonia from patients age 50+ was only 11.71%, yet, 
the majority of expenditure (56.95%) for pneumonia patients is in the ages 50+. 
Pneumonia prevention strategies, including vaccinations, targeting adults age 50+, 
could potentially reduce health care costs associated with this condition.
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objeCtives: To evaluate the economic burden of dengue from public payer and soci-
etal perspectives in Brazil. Methods: Investigation was designed as a multicenter 
cost study. Suspected dengue cases were recruited during 2012/2013 in four endemic 
regions (city): Midwest (Goiania), Southeast (Belo Horizonte and Rio de Janeiro), 
Northeast (Teresina and Recife), North (Belem). Participants were suspected or labo-
ratory confirmed dengue cases, treated in ambulatory or hospital settings (private 
and public sectors). A household interview was scheduled 20-30 days after the onset 
of clinical symptoms. The time horizon was one-year considering dengue seasonality. 
We calculated the direct cost, public payer perspective and direct/indirect costs for 
societal perspective. Estimation of annual national dengue costs took into account 
cases reported by notification system (SINAN) having possible under-reporting from 
passive surveillance. Results: We screened 2,223 patients and 2,097 (94.3%) sympto-
matic dengue cases were included. The majority of patients were adults. 1,661 cases 
were treated in ambulatory and 436 cases in hospitals. In the ambulatory cohort, the 
average number of medical visits ranged from 1.2 to 4.2. A higher number of medical 
visits were recorded among inpatients (3.2 to 5.0). For the public payer perspective, 
estimated cost per case was USD 43 (95% CI: 39-47) ambulatory and USD 237 (95% 
CI: 202-248) hospital. Dengue illness in Brazil was estimated to cost USD 126 million 
(95% CI: 112-135), ambulatory and hospitalized cases considering the reported cases 
(SINAN). Outpatients cost account for 62% of the total costs. For the societal perspec-
tive, the estimated cost per ambulatory case was USD 163 (95% CI: 142-169) and USD 
465 (95% CI: 407-591) hospital. Dengue illness was estimated to cost USD 389 million 
(95% CI: 339-425), ambulatory and hospitalized cases. ConClusions: Our results 
show evidence of substantial economic impact in Brazil. We have provided a timely 
economic evaluation of dengue.
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objeCtives: Hepatitis A virus (HAV) infection is self-limiting with no chronic 
complications but in some cases might be very severe causing significant number 
of deaths. The results of a previously conducted cost-benefit analysis demon-
strated that the vaccination of all 1-year old children in the general population 
would be cost-effective to the health care system only in the years with an epi-
demiologic outbreak. The question remains will it be cost-effective in population 
period. For vaccination with PCV13 versus PPSV23, incremental costs per patient 
were 29.13BRL (CM) and 28.97BRL (IC) leading to a budget impact of 444,074,277BRL 
(CM) and 37,846,568BRL (IC) for the same period. ConClusions: The addition of 
PCV13 to the immunization schedule in adults ≥ 18 years with comorbidities or 
immunocompromising condition would avoid more IPD cases, with an incremental 
cost varying from 37,846,568BRL to 793,005,843BRL over a 10 year period.
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objeCtives: Triclosan coated antibacterial sutures (TCS) are designed to control 
the bacterial colonization of the suture line, a known risk factor for surgical site 
infection (SSI). A recently published meta-analysis came to the conclusion that TCS 
showed a significant advantage in reducing the rate of SSI by 30 per cent (relative 
risk 0·70,95 per cent C. I. 0·57 to 0·85; P < 0·001). Subgroup analyses revealed con-
sistent results in favour of TCS in adult patients, abdominal procedures, and clean 
or clean-contaminated surgical wounds. A budget impact analysis (BIA) has been 
developed to estimate the cost saving associated with use of new technology from 
the Italian Health Service perspective over a 1 year time horizon. Methods: A lit-
erature review has been conducted to evaluate the potential impact of cost savings 
associated with SSI reduction in different procedures: Abdominal Hysterectomy; 
CABG; Colorectal Surgery; Hip Prothesis; Limb Amputation; Small Bowel Surgery. 
The means and 95% confidence interval (CI) for the BIA were estimated using boot-
strap methods (10.000 simulations) assuming lognormal distribution for costs and 
time data, and beta distribution for percentage data. Results: Potential cost sav-
ings per procedure with TCS would be 86€ for Abdominal Hysterectomy, 49€ for 
CABG, 141€ for Colorectal Surgery, 132€ for Hip Prothesis implantation, 415€ for 
Limb Amputation, 258€ for Small Bowel Surgery. Considering the annual procedures 
performed, the use of TCS, could be associated with cost saving of about 26.110.195 € 
(95%-CI: 10.574.295€ - 41.429.481€ ): 10% for Abdominal Hysterectomy; 1% for CABG; 
30% for Colorectal Surgery; 15% for Hip Prothesis; 34% for Limb Amputation and 8% 
for Small Bowel Surgery. ConClusions: The additional costs for TCS appear to be a 
cost-saving through the reduction of costs associated with SSI allowing budget to be 
reallocated for other activities within the Health Service/Hospital. The results were 
consistent according to the developed probabilistic sensitivity analysis.
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objeCtives: Analyse the budget impact in Region Hovedstaden in Denmark (Region 
H), if all Clostridium difficile (CDI) hospitalised patients received fidaxomicin instead 
of vancomycin during one year. Methods: The Danish national patient database 
provided the number of hospitalised patients and length of stay (LOS) for CDI patients 
(ICD-10: A047). A phase III trial provided the risk of a first and second CDI recur-
rence [Cornelly 2012]. Cost per hospital stay calculated by LOS multiplied by cost 
per bed day (DKK 6,000) plus drug costs, vancomycin (DKK 300), fidaxomicin (DKK 
11,641). Results: In Region H 840 CDI patients were hospitalised in 2012. Assuming 
the same outcome as the trial, the total number of CDI hospitalisations would 
decrease from 1,104 with vancomycin ((23,2% risk of 1st recurrence (23.2% *840 = 195); 
35.5% risk of 2nd recurrence (35.5%*195 = 69)) to 930 with fidaxomicin ((9.0% risk of 1st 
recurrence (9.0%*840= 76); 19.7% risk of 2nd recurrence (19.7% *76= 15)). Fidaxomicin 
prevents 174 hospitalisations compared to vancomycin. Assuming CDI is the primary 
diagnosis, with an average LOS of 9.0 days, the health care cost will increase by 2% 
with fidaxomicin. Assuming CDI is the secondary diagnosis, with an average LOS of 
16.8 days, the health care cost will decrease by 6% with fidaxomicin. Assuming the 
average LOS for CDI patients is 13.3 days, the health care cost will decrease with 4%, 
and assuming LOS is 10 days, using fidaxomicin is cost neutral. ConClusions: In 
Region H, if all hospitalised CDI patients received fidaxomicin the number of recur-
rences decreases by 66% and the total number of cases decreases by 16%, compared to 
vancomycin usage. From the health care payer perspective fidaxomicin reduces recur-
rences, frees up available bed days, and may be cost neutral or cost saving depending 
on the assumed LOS, compared to vancomycin.
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objeCtives: In 2002 routine vaccination with a pneumococcal conjugate vaccine 
(PCV) was introduced in the French vaccination calendar for infants and toddlers. 
Since then, an ecological impact has been observed in the incidence of pneumococ-
cal diseases in adults: incidence of invasive pneumococcal disease (IPD) of sero-
types covered by PCV decreased, and serotypes not covered by PCV increased. This 
study aimed to quantify public health and budget impact of several pneumococ-
cal vaccination strategies for at-risk adults in France over 5 years. Methods: The 
analysis was adapted from a population-based Markov model previously developed 
for Germany, consisting of five health states: no pneumococcal disease, IPD, non-
bacteraemic pneumococcal pneumonia (NBPP), post-meningitis sequelae and death. 
Epidemiology and costs were estimated from French sources whenever available. 
Uncertainty around vaccines effectiveness was handled using optimistic and/or 
pessimistic scenario analyses. At-risk adults received either PPV23 (for the immu-
nocompetent) or PCV13 (for the immunosuppressed). This strategy was compared 
to PCV13 vaccine alone. Results: Between 2014 and 2018, vaccination with PPV23 
and PCV13 led to a higher reduction in terms of IPD and NBPP cases avoided in most 
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objeCtives: To find out the average cost of hospitalization and length of hospital 
stay for patients infected with carbapenem-resistant bacteria and compare it with 
that of patients infected with carbapenem-sensitive bacteria. Methods: A cross 
sectional study was carried out for 3 months and the data for hospitalization cost 
was collected for the patients with carbapenem resistant and carbapenem sensi-
tive infections from the medicine ICU and the microbiology department for 114 
patients with bacterial infections who were admitted to Intensive care unit. The 
data was analyzed for the type of infection and the average hospitalization cost. The 
median hospitalization cost was calculated for both the group of patients. Results: 
Out of 247 patients admitted in the ICU during a three month period 70 (28.34%) 
were found to be having carbapenem-resistant infections and 44 (17.81%) were 
found to have carbapenem-sensitive infections. The median length of stay in the 
hospital was 9 days for carbapenem-sensitive patients while 23.5 days in case of 
carbapenem-resistant patients. The median hospitalization cost was found to be 
40185 INR in case of carbapenem sensitive patients while it was 126889.5 INR in 
case of carbapenem-resistant patients. ConClusions: Carbapenem-resistance is 
observed to be increasing the morbidity and cost burden on the patients substan-
tially. Increased length of hospital stay leads to an increase in the incidence of 
Nosocomial infections which further leads to the increased morbidity, mortality 
and cost burden on the society.
PIN33
tReatmeNt of mRsa PNeumoNIa: eCoNomICal aNd ClINICal 
ComPaRIsoN of lINezolId veRsus vaNComYCIN
Wilke M.1, Petrik C.2, Weber B.3, Kloss S.3
1Dr. Wilke GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Berlin, Germany, 3Pfizer Deutschland 
GmbH, Berlin, Germany
objeCtives: Infections with methicillin resistant Staphylococcus aureus (MRSA) 
pathogens represent a substantial economic burden for the health care system. 
Although the expenses directly related to the antibiotics used for the treatment of 
MRSA infections are generally negligible in relation to the total MRSA-related hospi-
tal costs, the prices of the drugs often influence the therapy decisions. The objective 
of this study was to investigate – in a clinical routine setting – the overall costs of 
stay on intensive care unit (ICU) and the clinical effectiveness of treatment with lin-
ezolid compared to vancomycin in patients with MRSA pneumonia. Methods: This 
was a retrospective analysis of reimbursement and medical data of adult patients 
who were treated for MRSA pneumonia in German hospitals between 2008 and 
2012. Propensity score adjustment was applied to reduce the effect of confound-
ing. Results: 95 of the 226 patients included received linezolid as initial therapy 
for MRSA pneumonia and 131 received vancomycin. The analysis of the total costs of 
stay on ICU did not reveal any major differences between the two treatment groups 
(cost ratio linezolid/vancomycin: 1.29; 95% confidence interval (CI): 0.84 – 1.98; p = 
0.24). Analyses of clinical data showed a decreased likelihood of therapy failure (= 
switch to another antibiotic) (logistic regression analysis; odds ratio linezolid/vanco-
mycin: 0.183; 95% CI: 0.052 – 0.647; p < 0.01) and a decreased risk of dying in hospital 
(Cox proportional hazard regression analysis; hazard ratio linezolid/vancomycin: 
0.508; 95% CI: 0.305 – 0.846; p < 0.01) in the linezolid group. ConClusions: Despite 
higher drug acquisition costs, the total costs of stay on ICU were not significantly 
higher in patients receiving linezolid than in patients receiving vancomycin. The 
clinical effectiveness, on the other hand, was superior: Both, the rate of therapy 
failures and the all-cause hospital mortality rate were substantially lower in patients 
who received linezolid.
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objeCtives: To compare treatment costs for the fixed dose combination (FDC) teno-
fovir and emtricitabine (TDF/FTC) versus FDC abacavir and lamivudine (ABC/3TC) 
each in combination with efavirenz (EFV) in treatment-naïve adults with HIV-1 
infection in Russia. Methods: A mathematical model was developed in Microsoft 
Excel to evaluate costs of treatment, including drug (1st and 2nd lines of therapy) 
and patient management costs. In the model individuals remained on their current 
regimen or moved to the 2nd line of therapy after the first 48 weeks on therapy. 
Transition probabilities were based on the proportion of patients with viral response 
measured as HIV-1 RNA < 50 copies per milliliter from the clinical trial with TDF/FTC 
+ EFV vs ABC/3TC + EFV head-to-head comparison. Cost calculations were based on 
registered drug prices, reimbursement rates in public medical insurance and data 
on government procurement in Russia in 2014. Results: It was expected that after 
the 48 weeks of treatment 71.0% of patients in TDF/FTC + EFV group and 59.4% of 
ABC/3TC +EFV remain on the initial regimen. The total average costs per patient 
for 96 weeks of therapy, including drug (1st and 2nd lines of therapy) and patient 
management costs, were lower for TDF/FTC + EFV (€ 6,528) than for ABC/3TC + EFV 
group (€ 7,123). ConClusions: FDC TDF/FTC in 1st line therapy in treatment-naïve 
adults with HIV-1 infection in combination with EFV was predicted to be cost-saving 
compared with FDC ABC/3TC+EFV for 96 weeks of treatment in Russian Federation.
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objeCtives: After each negotiation between a health care provider and a payer, 
financial risks exists that may jeopardize the payer’s budget. Risk-sharing agree-
ments (RSAs) in medical care can be used to reassure payers on budget trajectory. 
This has grown during the recent years resulting from increased budget restric-
groups in high risk. The aim of the study is to evaluate the economic consequences 
of the vaccination against HAV in population groups at high risk and to com-
pare the results with the vaccination of all 1-year old children in the popula-
tion. Methods: Cost-benefit analysis was performed based on epidemiologic 
data for the number of incidents in the high risk groups and the treatment cost of 
the HAV infected individuals. Those costs were compared with the cost of vaccina-
tion. Two vaccination scenarios were created 1. Prophylactic one dose vaccination 
and 2. One initial and one buster dose application. The validity of the results was 
tested with sensitivity analysis using tornado diagram. Results: The vaccina-
tion of all people in the high risk group (n= 32 606) induces savings for the health 
care system because the cost of vaccination is less than the cost of treatment of 
the people with HAV infection (n= 4565). The cost of vaccination varies from € 1 
257 322 to € 2 514 646 depending on the vaccination regimen: “first scenario” and 
“second scenario”, respectively. The expenditures for infected peoples’ therapy 
are € 2 547 254. Thus the net savings account for € 1 289 932 and € 32 608, respec-
tively. ConClusions: The analysis confirms that the vaccination against hepa-
titis A infection is cost-saving for the health care if performed in groups at high 
risk and in the periods of epidemic outbreaks.
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objeCtives: The new wave of HCV drugs reaching the market in 2014 offer higher 
cure rates and shorter treatment times; however, the new antivirals have been met 
with concerns regarding the costs associated with the new drugs by payors and the 
WHO. We have set out to examine the costs of treatment with sofosbuvir, compared 
to first generation antivirals in eight countries. Methods: We examined the ex-
manufacturer price of sofosbuvir, telaprevir and boceprevir in Norway, Denmark, 
Germany, Luxembourg, Portugal, Slovenia, Turkey, and the United States. Treatment 
costs were calculated using standard of care protocols for treatment of HCV genotype 
1, including individual daily dosage strength and length of recommended treatment 
for each antiviral. Interferon and ribavirin costs, any potential discounts or rebates 
negotiated with payors and potential follow-up courses of therapy for sofosbuvir were 
excluded from the study. Prices were extracted from IHS Life Sciences’ international 
pricing database POLI. All foreign currency was converted to USD using XE Currency 
Converter for comparison. Results: Costs of treatment with sofosbuvir varied signif-
icantly across the eight countries, being highest in the US at USD84,000 then Portugal 
at USD75,816 down to USD52,051 in Norway. Telaprevir and boceprevir treatment costs 
range from a low of USD21,534 and USD14,111 in Turkey respectively, to a high of 
USD66,155 and USD40,120 in the US. On average across the eight countries, treatment 
with sofosbuvir was 104% higher than telaprevir, and 187% higher than boceprevir, 
based on the list price. ConClusions: Our preliminary assessment has highlighted 
the variable treatment costs of HCV antivirals across countries. Comparisons of treat-
ment costs with next generation treatments versus first-generation antivirals will 
see expenditure for HCV therapeutics increase significantly. However, sofosbuvir has 
demonstrated cure rates of over 95% in genotype 1 HCV patients with a favourable 
safety profile, thus reducing costs of re-treatment, medical visits, and treatment of 
advanced liver disease.
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objeCtives: To prevent reactivation of hepatitis B virus (HBV) following chemother-
apy or immunosuppressive therapy, appropriate clinical managements including 
HBV screening and antiviral prophylaxis for patients at risk of reactivation should 
be provided. Cost information of managing HBV reactivation is needed to evaluate 
cost-effectiveness of HBV prevention strategies in Japan. Methods: Annual number 
of patients who have received cancer chemotherapy, biologic therapy for rheumatoid 
arthritis, or stem-cell / organ transplantation was estimated using information of 
national statistics and expert opinions. Costs of HBV screening and antiviral prophy-
laxis were calculated by following the HBV reactivation management guideline and 
reimbursement prices. A Markov model was created to compare two vaccination 
strategies of HBV infections (current selective vaccine program vs. new universal 
vaccine program) by considering risk of receiving chemotherapy or immunosuppres-
sive therapy, management costs of HBV reactivation, and disease-specific mortality, 
during 90 years of follow-up. Results: Costs for HBV reactivation management were 
estimated 688 yen per person in selective vaccination strategy compared with 350 
yen per person in universal vaccination strategy, with annual discount rate of 3%. 
On one-way sensitivity analysis, estimated costs were sensitive to annual discount 
rates and risks of HBV infections. ConClusions: Absolute difference in the HBV 
management costs was relatively small compared with vaccine program costs. Since 
the management of HBV reactivation was not always provided for all patients at risk, 
a further cost analysis should be conducted by reflecting real-world clinical practice.
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